Search

Displaying results 5831 - 5840 of 7895 in total
  1. Drug

    AVI-7537

    go.drugbank.com/drugs/DB15433
    Investigational

    AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication. … [L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers).

  2. Drug

    Batroxobin

    go.drugbank.com/drugs/DB09005
    Investigational

    Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. … Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity.

    Categories: Venombin AInternational brands: Ba Qu Ting
  3. Drug

    Cabamiquine

    go.drugbank.com/drugs/DB21477
    Investigational

    Cabamiquine is a small molecule drug. … Cabamiquine has a monoisotopic molecular weight of 462.24 Da.

  4. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42330] It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. … [A249920] LetibotulinumtoxinA is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26.

    Synonyms: BoNT/A-DSCategories: Botulinum Toxins, Type A
  5. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative … [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

  6. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … complications in surgical patients at risk of COVID-19.

  7. Drug

    Cariporide

    go.drugbank.com/drugs/DB06468
    Experimental

  8. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).

  9. Drug

    3-amino-5-phenylpentane

    go.drugbank.com/drugs/DB02869
    Experimental

    These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by a propan-1-amine. 3-amino-5-phenylpentane targets the proteins cathepsin K … 3-amino-5-phenylpentane is a solid. This compound belongs to the phenylpropylamines.

  10. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).